Loading
A phase 2 trial of irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM in glioma & glioblastoma, run by CRISM Therapeutics LTD, now recruiting.
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma is a phase 2 interventional study registered as NCT07356973 by CRISM Therapeutics LTD, with 147 participants planned, started 2026-08-20 and due to reach its primary completion in 2029-05. Interventions recorded: irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/